They identified a range of diagnostic biomarkers for prostate cancer which included Alpha-1-Microglobulin/Bikunin Precursor (AMBP), Cluster of Differentiation 59 (CD59), Inter-alpha-trypsin Inhibitor Heavy Chain 4 (ITIH4), Prostaglandin D2 Synthase (PTGDS), Secreted and Transmembrane 1 (SCTM1), and Haptoglobin (HP). Here, SECTM1 is linked to prostate carcinoma.